AU2017360910B2 - Compositions and methods for the treatment of opioid overdose - Google Patents

Compositions and methods for the treatment of opioid overdose Download PDF

Info

Publication number
AU2017360910B2
AU2017360910B2 AU2017360910A AU2017360910A AU2017360910B2 AU 2017360910 B2 AU2017360910 B2 AU 2017360910B2 AU 2017360910 A AU2017360910 A AU 2017360910A AU 2017360910 A AU2017360910 A AU 2017360910A AU 2017360910 B2 AU2017360910 B2 AU 2017360910B2
Authority
AU
Australia
Prior art keywords
patient
nalmefene
recited
maltoside
sucroside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017360910A
Other languages
English (en)
Other versions
AU2017360910A1 (en
Inventor
Roger CRYSTAL
Edward T. Maggio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indivior Inc
Aegis Therapeutics LLC
Original Assignee
Indivior Inc
Aegis Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017360910(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Inc, Aegis Therapeutics LLC filed Critical Indivior Inc
Publication of AU2017360910A1 publication Critical patent/AU2017360910A1/en
Application granted granted Critical
Publication of AU2017360910B2 publication Critical patent/AU2017360910B2/en
Assigned to AEGIS THERAPEUTICS, LLC, INDIVIOR INC. reassignment AEGIS THERAPEUTICS, LLC Amend patent request/document other than specification (104) Assignors: AEGIS THERAPEUTICS, LLC, OPIANT PHARMACEUTICALS, INC.
Priority to AU2024201047A priority Critical patent/AU2024201047A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017360910A 2016-11-18 2017-11-09 Compositions and methods for the treatment of opioid overdose Active AU2017360910B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201047A AU2024201047A1 (en) 2016-11-18 2024-02-19 Compositions and methods for the treatment of opioid overdose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424378P 2016-11-18 2016-11-18
US62/424,378 2016-11-18
PCT/US2017/060964 WO2018093666A1 (en) 2016-11-18 2017-11-09 Compositions and methods for the treatment of opioid overdose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201047A Division AU2024201047A1 (en) 2016-11-18 2024-02-19 Compositions and methods for the treatment of opioid overdose

Publications (2)

Publication Number Publication Date
AU2017360910A1 AU2017360910A1 (en) 2019-05-30
AU2017360910B2 true AU2017360910B2 (en) 2023-11-23

Family

ID=62146061

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017360910A Active AU2017360910B2 (en) 2016-11-18 2017-11-09 Compositions and methods for the treatment of opioid overdose
AU2024201047A Pending AU2024201047A1 (en) 2016-11-18 2024-02-19 Compositions and methods for the treatment of opioid overdose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201047A Pending AU2024201047A1 (en) 2016-11-18 2024-02-19 Compositions and methods for the treatment of opioid overdose

Country Status (9)

Country Link
US (3) US11458091B2 (enExample)
EP (1) EP3541386A4 (enExample)
JP (2) JP7312698B2 (enExample)
CN (1) CN110139651A (enExample)
AU (2) AU2017360910B2 (enExample)
CA (1) CA3044221A1 (enExample)
IL (2) IL312012A (enExample)
RU (1) RU2769397C2 (enExample)
WO (1) WO2018093666A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US11458091B2 (en) 2016-11-18 2022-10-04 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2019222408A1 (en) * 2018-05-17 2019-11-21 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
US20210228570A1 (en) * 2018-06-01 2021-07-29 Purdue Pharma L.P. Compositions and methods for opioid overdose rescue
JP7549576B2 (ja) * 2018-11-06 2024-09-11 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイドアンタゴニストを送達するための組成物及び方法
US20210401827A1 (en) * 2018-11-07 2021-12-30 Opiant Pharmaceuticals, Inc. Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
CN114144224B (zh) 2019-03-26 2024-08-09 保科特纳洛克斯恩公司 药物合成物输送器械和方法
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
CA3167312A1 (en) * 2020-02-07 2021-08-12 Stephen J. Lewis Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
JP2023525019A (ja) * 2020-05-04 2023-06-14 アンファスター・ファーマスーティカルズ・インコーポレイション 薬剤の経鼻送達のための促進剤としての胆汁酸及びその塩の安全な使用
IL297658A (en) 2020-05-18 2022-12-01 Orexo Ab Pharmaceutical preparation for drug administration
CA3187753A1 (en) * 2020-07-29 2022-02-03 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient
US20220387407A1 (en) * 2021-02-08 2022-12-08 Case Western Reserve University Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023014906A1 (en) * 2021-08-04 2023-02-09 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
KR20240103005A (ko) 2021-11-25 2024-07-03 오렉쏘 에이비 아드레날린을 포함하는 약학적 조성물
WO2024222920A1 (zh) * 2023-04-28 2024-10-31 成都苑东生物制药股份有限公司 一种用于鼻内给药的药物制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
WO2015136373A1 (en) * 2014-03-14 2015-09-17 Lightlake Therapeutics Inc. Nasal drug products and methods of their use
WO2016007729A1 (en) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
WO2017223566A1 (en) * 2016-06-24 2017-12-28 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of alcohol use disorder

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4880813A (en) 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US5069895A (en) 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
IL97075A0 (en) 1990-02-14 1992-03-29 Alcon Lab Inc Topical pharmaceutical composition containing an alkyl saccharide
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
JP2005508888A (ja) 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
CN1305474C (zh) * 2004-10-13 2007-03-21 北京国药龙立生物医药新技术有限公司 盐酸纳美芬鼻腔给药制剂
US20070212307A1 (en) 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
US20100076006A1 (en) 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US20110065628A1 (en) 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
WO2009128474A1 (ja) 2008-04-16 2009-10-22 財団法人化学及血清療法研究所 トロンビン固定化生体吸収性シート製剤の製造方法
JP5843873B2 (ja) 2010-10-29 2016-01-13 トロイカ ファーマスーティカルズ リミテッド ビタミンｂ１２の鼻内用組成物
EP2720699B1 (en) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140171458A1 (en) 2012-12-13 2014-06-19 3B Pharmaceuticals, Inc. Intranasal naltrexone
DE202013105715U1 (de) 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
US20160256472A1 (en) 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US20190262263A1 (en) 2016-11-09 2019-08-29 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions
US11458091B2 (en) 2016-11-18 2022-10-04 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
CN106361700A (zh) 2016-11-25 2017-02-01 威海恒基伟业信息科技发展有限公司 盐酸纳美芬鼻腔给药制剂
WO2019222408A1 (en) 2018-05-17 2019-11-21 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
US20210401827A1 (en) 2018-11-07 2021-12-30 Opiant Pharmaceuticals, Inc. Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
PH12021551465A1 (en) 2018-12-20 2022-04-11 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) 2018-12-20 2020-12-17 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
WO2015136373A1 (en) * 2014-03-14 2015-09-17 Lightlake Therapeutics Inc. Nasal drug products and methods of their use
US20150258019A1 (en) * 2014-03-14 2015-09-17 Lightlake Therapeutics, Inc. Nasal drug products and methods of their use
WO2016007729A1 (en) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
WO2017223566A1 (en) * 2016-06-24 2017-12-28 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of alcohol use disorder

Also Published As

Publication number Publication date
AU2017360910A1 (en) 2019-05-30
CA3044221A1 (en) 2018-05-24
IL266674A (en) 2019-07-31
IL266674B2 (en) 2024-09-01
RU2769397C2 (ru) 2022-03-31
US20200060967A1 (en) 2020-02-27
EP3541386A4 (en) 2020-05-27
JP7730443B2 (ja) 2025-08-28
JP7312698B2 (ja) 2023-07-21
US20250127712A1 (en) 2025-04-24
IL312012A (en) 2024-06-01
IL266674B1 (en) 2024-05-01
JP2019534315A (ja) 2019-11-28
US20220387306A1 (en) 2022-12-08
US11458091B2 (en) 2022-10-04
AU2024201047A1 (en) 2024-03-14
RU2019118465A (ru) 2020-12-18
JP2023140359A (ja) 2023-10-04
RU2019118465A3 (enExample) 2021-03-04
EP3541386A1 (en) 2019-09-25
CN110139651A (zh) 2019-08-16
WO2018093666A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
US20250127712A1 (en) Compositions and methods for the treatment of opioid overdose
JP7492548B2 (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
US20210275519A1 (en) Nasal drug products and methods of their use
US9211253B2 (en) Nasal drug products and methods of their use
US20210077382A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
US20230225961A1 (en) Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
US20240197719A1 (en) Formulations and methods for the prevention of opioid overdose
US12290596B2 (en) Compositions and methods for the treatment of opioid overdose

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AEGIS THERAPEUTICS, LLC

Free format text: FORMER NAME(S): OPIANT PHARMACEUTICALS, INC. ; AEGIS THERAPEUTICS, LLC

Owner name: INDIVIOR INC.

Free format text: FORMER NAME(S): OPIANT PHARMACEUTICALS, INC. ; AEGIS THERAPEUTICS, LLC

FGA Letters patent sealed or granted (standard patent)